Appeal No. 2001-1970 Page 2
Application No. 08/260,190
36. A method according to Claim 30 wherein said MN antisense
oligonucleotide is selected from the group consisting of SEQ ID NOS: 3, 4 and 7.
The examiner relies on the following references:
Hoke et al. 5,585,479 Dec. 17, 1996
Wagner, “Gene Inhibition using Antisense Oligodeoxynucleotides,” Nature,
Vol. 372, pp. 333-335 (1994)
Rojanasakul, “Antisense Oligonucleotide Therapeutics : Drug Delivery and
Targeting,” Advanced Drug Delivery Reviews, Vol. 18, pp. 115-131 (1996)
Gura, “Antisense Has Growing Pains,” Science, Vol. 270, pp. 575-577 (1995)
Reynolds, “First Antisense Drug Trials Planned In Leukemia,” Journal of the
National Cancer Institute, Vol. 84, pp. 288-289 (1992)
Stein et al., “Antisense Oligonucleotides as Therapeutic Agents – Is the Bullet
Really Magical ?” Science, Vol. 261, pp. 1004-1012 (1993)
Wu-Pong, “Oligonucleotides: Opportunities for Drug Therapy and Research,”
Pharmaceutical Technology, Vol. 18, pp. 102-114 (1994)
Stull et al. (Stull), “Antigene, Ribozyme and Aptamer Nucleic Acid Drugs :
Progress and Prospects,” Pharmaceutical Research, Vol. 12, pp. 465-483 (1995)
Milligan et al., “Current Concepts in Antisense Drug Design,” Journal of Medicinal
Chemistry, Vol. 36, No. 14, pp. 1923-1937 (1993)
Branch, “A good antisense molecule is hard to find,” TIBS, Vol. 23, pp. 45-50
(1998)
Tseng et al., “Antisense Oligonucleotide Technology in the Development of
Cancer Therapeutics,” Cancer Gene Therapy, Vol. 1, No. 1, pp. 65-71 (1994)
Miller et al., “ Gene Transfer and Antisense Nucleic Acid Techniques,”
Parasitology Today, Vol. 10, No. 3, pp. 92-97 (1994)
James, “Towards Gene-Inhibition Therapy: A Review of Progress and Prospects
in the Field of Antiviral Antisense Nucleic Acids and Ribozymes,” Antiviral
Chemistry & Chemotherapy, Vol. 2, No. 4, pp. 191-214 (1991)
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007